APELOA Pharmaceutical Co., Ltd. (STOCK CODE: 000739), a member of Hengdian Group, devotes itself to providing efficient, flexible and high-quality solutions for pharmaceutical productis to global needs. APELOA is committed to the research & development, production, and sales of intermediates, APIs, and finished dosage. In addition, Apeloa offers one-stop CDMO service to global pharmaceutical companies. The company owns 7 production sites (5 chemical synthesis & 2 biological fermentation) for API/Intermediates and CDMO, and 3 productions sites for FDF. Apeloa has an excellent tracking records with regulatory authorities including US FDA, EDQM, PMDA, CFDA. In 2019, APELOA achieved annual sales of 1.03 billion US dollars, over 13% of year-on-year growth, and 82 million US dollars profit, a 49% of year-on-year increase. In the recent report from the MIIT (Ministry of Industry and Information Technology of the People’s Republic of China), APELOA ranked 49th from TOP 100 Chinese Pharmaceutical Companies, also ranked as 2nd for API exporter. In the other hand, APELOA ranked 21st in “China's top 100 pharmaceutical industry in 2019” List which published by Minet, a rating platform that sponsored by CFDA.